Traders purchased shares of Gilead Sciences Inc. (NASDAQ:GILD) on weakness during trading on Monday. $258.41 million flowed into the stock on the tick-up and $222.17 million flowed out of the stock on the tick-down, for a money net flow of $36.24 million into the stock. Of all stocks tracked, Gilead Sciences had the highest net in-flow for the day. Gilead Sciences traded down ($1.60) for the day and closed at $78.17

GILD has been the topic of several recent research reports. Piper Jaffray Cos. reissued a “buy” rating and issued a $108.00 price target on shares of Gilead Sciences in a research note on Monday, August 15th. Morgan Stanley reissued a “hold” rating and issued a $103.00 price target on shares of Gilead Sciences in a research note on Wednesday, June 15th. Jefferies Group reissued a “hold” rating and issued a $97.00 price target on shares of Gilead Sciences in a research note on Friday, July 15th. Maxim Group reissued a “hold” rating on shares of Gilead Sciences in a research note on Sunday, July 10th. Finally, Vetr raised Gilead Sciences from a “buy” rating to a “strong-buy” rating and set a $105.06 price target on the stock in a research note on Monday, May 2nd. Ten equities research analysts have rated the stock with a hold rating, sixteen have given a buy rating and three have given a strong buy rating to the company. The company currently has an average rating of “Buy” and a consensus target price of $106.82.

The stock has a 50-day moving average of $82.09 and a 200 day moving average of $87.13. The company has a market capitalization of $103.16 billion and a P/E ratio of 6.86.

Gilead Sciences (NASDAQ:GILD) last issued its quarterly earnings results on Monday, July 25th. The biopharmaceutical company reported $3.08 earnings per share (EPS) for the quarter, topping the Thomson Reuters’ consensus estimate of $3.02 by $0.06. During the same quarter in the previous year, the business earned $3.15 EPS. The company had revenue of $7.78 billion for the quarter, compared to analysts’ expectations of $7.80 billion. The company’s revenue for the quarter was down 5.7% on a year-over-year basis. Analysts predict that Gilead Sciences Inc. will post $11.78 EPS for the current fiscal year.

The firm also recently disclosed a quarterly dividend, which will be paid on Thursday, September 29th. Investors of record on Friday, September 16th will be issued a $0.47 dividend. This represents a $1.88 annualized dividend and a yield of 2.41%. The ex-dividend date is Wednesday, September 14th.

In related news, insider John C. Martin sold 100,000 shares of the firm’s stock in a transaction that occurred on Monday, August 1st. The shares were sold at an average price of $80.50, for a total value of $8,050,000.00. Following the completion of the transaction, the insider now directly owns 4,119,727 shares of the company’s stock, valued at approximately $331,638,023.50. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this link. Also, EVP Paul Rutherford Carter sold 2,000 shares of the firm’s stock in a transaction that occurred on Monday, August 1st. The stock was sold at an average price of $79.81, for a total transaction of $159,620.00. Following the completion of the transaction, the executive vice president now directly owns 64,122 shares of the company’s stock, valued at $5,117,576.82. The disclosure for this sale can be found here.

Other hedge funds and institutional investors have added to or reduced their stakes in the company. BNP Paribas Arbitrage SA increased its position in Gilead Sciences by 43.3% in the fourth quarter. BNP Paribas Arbitrage SA now owns 3,213,246 shares of the biopharmaceutical company’s stock valued at $325,148,000 after buying an additional 970,463 shares during the period. Mizuho Trust & Banking Co. Ltd. increased its position in Gilead Sciences by 1.0% in the fourth quarter. Mizuho Trust & Banking Co. Ltd. now owns 2,277,664 shares of the biopharmaceutical company’s stock valued at $232,686,000 after buying an additional 23,105 shares during the period. Cornerstone Capital Management Holdings LLC. increased its position in Gilead Sciences by 3.0% in the fourth quarter. Cornerstone Capital Management Holdings LLC. now owns 722,425 shares of the biopharmaceutical company’s stock valued at $73,102,000 after buying an additional 21,123 shares during the period. Coho Partners Ltd. increased its position in Gilead Sciences by 2.0% in the fourth quarter. Coho Partners Ltd. now owns 704,635 shares of the biopharmaceutical company’s stock valued at $71,302,000 after buying an additional 14,145 shares during the period. Finally, Gulf International Bank UK Ltd increased its position in Gilead Sciences by 2.4% in the fourth quarter. Gulf International Bank UK Ltd now owns 436,617 shares of the biopharmaceutical company’s stock valued at $44,181,000 after buying an additional 10,350 shares during the period.

Gilead Sciences, Inc is a research-based biopharmaceutical company. The Company focuses on the discovery, development and commercialization of medicines in areas of unmet medical need. The Company’s principal areas of focus include human immunodeficiency virus (HIV), liver diseases, such as chronic hepatitis C virus infection and chronic hepatitis B virus infection, cardiovascular, hematology/oncology and inflammation/respiratory.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.